title: The 4th study of prophylactic intravesical chemotherapy with adriamycin in the treatment of superficial bladder cancer: the experience of the Japanese Urological Cancer Research Group for Adriamycin.
abstract: A multicentric randomised trial was conducted for the purpose of investigating the efficacy of intravesical chemoprophylaxis of superficial bladder cancers. A total of 443 patients (number of evaluable patients, 284) were registered from July 1987 to December 1989 and randomised into 3 groups. Group A received 21 intravesical instillations of Adriamycin (ADM) at 20 mg/40 ml physiological saline for 2 years after undergoing transurethral resection (TUR); group B was given the same dose as group A but received 6 intravesical instillations for 2 weeks before undergoing TUR; and group C served as a control and underwent TUR only. Better prophylactic effects were obtained in group A. The overall non-recurrence rates calculated for groups A and B differed significantly (P less than 0.05) on day 240, and those determined for groups A and C were also significantly different (P less than 0.01) on day 480. No benefit was obtained using intravesical instillation prior to TUR (group B). The major side effects encountered were pollakisuria and miction pain, which occurred in 32% of the patients in group A and in 52% of those in group B.
authors.affiliation: Department of Urology, Kobe West City Hospital, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Matsumura
authors.forename: H
authors.initials: H
authors.lastname: Akaza
authors.forename: S
authors.initials: S
authors.lastname: Isaka
authors.forename: S
authors.initials: S
authors.lastname: Kagawa
authors.forename: K
authors.initials: K
authors.lastname: Koiso
authors.forename: T
authors.initials: T
authors.lastname: Kotake
authors.forename: T
authors.initials: T
authors.lastname: Machida
authors.forename: T
authors.initials: T
authors.lastname: Niijima
authors.forename: K
authors.initials: K
authors.lastname: Obata
authors.forename: Y
authors.initials: Y
authors.lastname: Ohashi
mesh_terms: D000283:Administration, Intravesical; D000368:Aged; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000517:prevention & control / Q000601:surgery; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000601:surgery
chemical_list: D004317:Doxorubicin